|
Blood test interval
|
Valid blood tests (n)
|
Number of abnormal test results (n (%))
|
Sensitivity/specificity
|
Likelihood ratio of cancer (95% CI)
|
Post-test probability of cancer (95% CI)†
|
|---|
|
Inflammation
|
|
High CRP
|
1474
|
438 (30%)
|
0.60/0.74
|
2.4 (2.0; 2.7)
|
24.7 (21.9; 27.6)
|
|
High ESR
|
1154
|
375 (32%)
|
0.61/0.72
|
2.2 (1.9; 2.6)
|
23.3 (20.6; 26.3)
|
|
Immunology
|
|
IgA
|
1473
| | | | |
|
Low
| |
46 (3%)
|
0.08/0.98
|
3.1 (1.7; 5.7)
|
30.1 (19.0; 44.2)
|
|
High
| |
108 (7%)
|
0.10/0.93
|
1.4 (0.9; 2.3)
|
16.5 (10.9; 24.2)
|
|
IgG
|
1472
| | | | |
|
Low
| |
78 (5%)
|
0.08/0.95
|
1.7 (1.0; 2.9)
|
19.1 (12.1; 28.8)
|
|
High
| |
71 (5%)
|
0.08/0.96
|
1.8 (1.0; 3.1)
|
19.6 (12.2; 30.0)
|
|
IgM
|
1474
| | | | |
|
Low
| |
114 (8%)
|
0.13/0.91
|
1.4 (0.9; 2.1)
|
16.5 (11.6; 22.9)
|
|
High
| |
123 (8%)
|
0.12/0.92
|
1.6 (1.0; 2.4)
|
17.7 (12.2; 24.9)
|
|
Haematology
|
|
White blood cell count
|
1486
| | | | |
|
Low
| |
20 (1%)
|
0.01/0.99
|
0.4 (0.1; 2.8)
|
5.0 (0.7; 28.1)
|
|
High
| |
226 (15%)
|
0.24/0.86
|
1.7 (1.3; 2.3)
|
19.5 (15.3; 24.5)
|
|
Neutrophil count
|
1469
| | | | |
|
Low
| |
56 (4%)
|
0.02/0.96
|
0.6 (0.2; 1.6)
|
7.4 (2.8; 17.8)
|
|
High
| |
204 (14%)
|
0.29/0.88
|
2.5 (1.8; 3.3)
|
25.6 (20.7; 31.2)
|
|
High eosinophil count
|
1469
|
62 (4%)
|
0.06/0.96
|
1.6 (0.9; 3.0)
|
18.2 (10.6; 29.6)
|
|
High basophil count
|
1468
|
41 (3%)
|
0.03/0.97
|
1.0 (0.4; 2.6)
|
12.6 (5.4; 26.5)
|
|
High metamyelocytes
|
1468
|
161 (11%)
|
0.24/0.91
|
2.5 (1.9; 3.5)
|
26.1 (20.5; 32.7)
|
|
Monocyte count
|
1468
| | | | |
|
Low
| |
13 (1%)
|
0.06/0.99
|
0.6 (0.1; 4.7)
|
7.9 (1.1; 39.7)
|
|
High
| |
473 (32%)
|
0.51/0.70
|
1.7 (1.4; 2.0)
|
19.1 (16.6; 21.9)
|
|
Lymphocyte count
|
1469
| | | | |
|
Low
| |
360 (25%)
|
0.42/0.78
|
1.9 (1.6; 2.3)
|
20.8 (17.7; 24.4)
|
|
High
| |
42 (3%)
|
0.02/0.97
|
0.8 (0.3; 2.2)
|
9.8 (3.8; 23.2)
|
|
Platelet count
|
1481
| | | | |
|
Low
| |
72 (5%)
|
0.10/0.96
|
2.4 (1.5; 4.0)
|
25.1 (16.7; 35.8)
|
|
High
| |
210 (14%)
|
0.25/0.87
|
2.0 (1.5; 2.6)
|
21.5 (17.0; 26.8)
|
|
Anaemia
|
|
Low haemoglobin
|
1482
|
428 (29%)
|
0.48/0.74
|
1.8 (1.5; 2.2)
|
20.1 (17.4; 23.1)
|
|
Iron deficiency anaemia
|
1470
|
83 (6%)
|
0.08/0.95
|
1.4 (0.8; 2.5)
|
16.7 (10.4; 25.9)
|
|
Anaemia, other causes
|
1452
|
145 (10%)
|
0.11/0.89
|
1.1 (0.7; 1.7)
|
12.9 (8.7; 18.7)
|
|
Combined anaemia
|
1452
|
25 (2%)
|
0.04/0.98
|
2.8 (1.2; 6.7)
|
28.3 (14.3; 48.2)
|
|
Inflammatory anaemia
|
1452
|
159 (11%)
|
0.25/0.91
|
2.8 (2.1; 3.8)
|
28.0 (22.2; 34.6)
|
|
Liver and metabolism
|
|
Low albumin
|
1494
|
361 (24%)
|
0.41/0.78
|
1.9 (1.5; 2.3)
|
20.7 (17.6; 24.2)
|
|
High ALT
|
1484
|
118 (8%)
|
0.12/0.93
|
1.7 (1.1; 2.6)
|
18.7 (13.0; 26.3)
|
|
High alkaline phosphatase
|
1479
|
257 (17%)
|
0.37/0.85
|
2.5 (2.0; 3.2)
|
26.0 (21.8; 30.7)
|
|
High bilirubin
|
1479
|
38 (3%)
|
0.07/0.98
|
3.3 (1.7; 6.4)
|
31.5 (19.1; 47.2)
|
|
High amylasec
|
1070
|
51 (5%)
|
0.04/0.95
|
0.9 (0.4; 2.0)
|
10.7 (5.0; 21.7)
|
|
High calcium
|
1484
|
119 (8%)
|
0.18/0.93
|
2.8 (1.9; 4.0)
|
27.7 (21.0; 35.7)
|
|
High LDH
|
1429
|
160 (11%)
|
0.22/0.90
|
2.3 (1.6; 3.1)
|
23.9 (18.5; 30.4)
|
|
High uric acid
|
1484
|
119 (8%)
|
0.09/0.92
|
1.1 (0.7; 1.9)
|
13.4 (8.6; 20.4)
|
|
Tumour markers
|
|
High M-proteinc
|
1050
|
33 (3%)
|
0.09/0.98
|
4.3 (2.2; 8.4)
|
37.4 (23.3; 54.0)
|
|
sFLC ratio
|
1455
| | | | |
|
Low
| |
30 (2%)
|
0.05/0.98
|
2.6 (1.2; 5.8)
|
26.7 (12.3; 45.9)
|
|
High
| |
201 (14%)
|
0.16/0.87
|
1.2 (0.8; 1.7)
|
13.9 (9.5; 19.5)
|
|
High AFP
|
1446
|
159 (11%)
|
0.10/0.89
|
0.9 (0.6; 1.4)
|
11.0 (7.2; 16.4)
|
|
High PSAa
|
694
|
97 (14%)
|
0.24/0.88
|
1.9 (1.3; 2.9)
|
21.1 (15.1; 28.6)
|
|
High hCGa
|
684
|
37 (5%)
|
0.18/0.97
|
5.8(3.1; 10.6)
|
44.4 (30.3; 59.6)
|
|
High CA-125b
|
769
|
93 (12%)
|
0.39/0.91
|
4.2 (2.9; 6.1)
|
36.8 (28.7; 45.7)
|
-
Abbreviations: ESR erythrocyte sedimentation rate, CRP C-reactive protein, IgA immunoglobulin A, IgG immunoglobulin G, IgM immunoglobulin M, ALT alanine aminotransaminase, LDH lactate dehydrogenase, sFLC serum-free light chain κ/λ ratio, AFP alpha-fetoprotein, PSA prostate-specific antigen, hCG human chorionic gonadotropin, CA-125 cancer antigen 125
-
†The pretest probability of cancer was 12.2%; a likelihood ratio of >1.0 increased the probability of cancer. aPSA and hCG were only performed in men
-
bCA-125 was only performed in women
-
cAs the reference range was changed for M protein and amylase during the inclusion period by the Department of Clinical Chemistry at Silkeborg Regional Hospital, we did not include test results for these blood tests after this change
